The usual causes of brain death are intra-cranial haemorrhage (45070), trauma (450/0) and hypoxicischaemic brain damage l . In the potential organ donor, once brain death has occurred, the circulation must continue to be supported and respiration artificially maintained, not only preoperatively but throughout the often protracted surgery required for the retrieval of multiple organs. At this time, there is a shift in emphasis of management, from cerebral resuscitation with its usual accompaniment of intravascular volume contraction, to the optimization of oxygen delivery to the rest of the body and maintenance of good organ and tissue perfusion. At the same time, the normal physiologic sequelae of brain death result in major changes in the cardiovascular system and in metabolic and electrolyte homeostasis which will eventually result in somatic death. In the potential donor, these must be anticipated and corrected.
MANAGEMENT OF THE POTENTIAL ORGAN DONOR INCLUDES:
1. recognition of the potential donor, 2. determination and certification of brain death 3. request for and consent to organ donation, 4. legal formalities, 5. support of the organ donor and optimization of organ function, 6. organization and co-ordination of organ procurement teams and operating theatre, 7. organ procurement. This paper will deal only with the recognition and support of the potential organ donor and the preservation of optimal organ function.
RECOGNITION OF THE POTENTIAL ORGAN DONOR
In the past, criteria for organ donation followed strict rules with respect to the age of the donor and the avoidance of high-dose inotropes to maintain blood pressure. Although it has been estimated that only 3 to 4070 of hospital deaths result in a potential organ donor and only 12 to 15070 of these become actual donors 2 , the reality is that only a very small percentage of hospital deaths occur in ventilated patients, and very few of these are potential organ donors. In Victoria, more than 50070 of those that meet the requirements of brain death become organ donorsl. The shortage of transplantable organs is such that in practice, very few rules are now absolute. Any comatose patient with irreversible cerebral disease who appears likely to progress to brain death prior to terminal circulatory failure or cardiac arrest should be considered a potential organ donor. The following criteria must be met. 1. Known aetiology of the terminal illness. 2. Absence of malignancy other than primary intracranial and non-melanotic skin cancers. 3. Absence of infections such as HIV, hepatitis, tuberculosis, septicaemia, fungaemia and disseminated viral infections. 4. Donor must not be in a "high risk" group for HIV infection. High-risk groups include: practising homosexuals, a homosexual experience in the last five years, bisexuals, intravenous drug users, sex workers, clients of sex workers, haemophiliacs, partners of a person in a high-risk group, or people who have had skin-piercing treatment in the last six months. It is extremely important to exclude those in high-risk groups, not only because there is a "window period" during which infection is present but serology is not yet positive, but because many potential donors are administered large volumes of blood as part of the resuscitation process and subsequent serology may then be doubtful or even negative. In these cases, attempts should be made to perform serology testing on the first blood sample taken on presentation to the hospital. Although all precautions are taken, and all appropriate tests are performed, there remains a minute possibility of transmission of viruses by donated organs. This risk is variable, but in Victoria, data provided by Red Cross Blood Bank indicates that the risk of transmission by blood products for Hepatitis C is approximately 1:4000, for Hepatitis B is approximately 1:250,000, and for HIV is approximately 1:1,000,000. Organ recipients must be informed of these risks. 5. Absence of previous treatment with human pituitary extracts. 6. Absence of absolute contraindications relevant to the particular organ system considered for retrieval ( Table I) . Age is no longer an absolute criterion, organs being accepted from donors in their seventies.
COMPLICATIONS OF BRAIN DEATH
In a review of 114 solid organ donors, Nygaard 3 found the following incidence of complications: hypotension (81070), multiple transfusion requirements (63070), diabetes insipidus (53070), disseminated intravascular coagulation (28070), arrhythmias (27070), cardiac arrest requiring cardio-pulmonary resuscitation (25070) pulmonary oedema (19070), hypoxia (II 070), acidosis (11 070), seizures (10070), and hypothermia (4070). Of those requiring multiple blood transfusions, 26070 received more than six units and l3070 more than ten units. In our experience, hypotension, diabetes insipidus and hypothermia are almost universal both in adults and children; seizures are common in adults but rare in children, and disseminated intravascular coagulation and cardiac arrest requiring cardiopulmonary resuscitation almost never seen. McArthur 4 reports similar findings to ours, with 86070 of organ donors having cardiovascular instability requiring inotropes and diabetes insipidus occurring in 93070.
With regard to the need for multiple blood transfusions, these are rarely needed in the management of intra-cerebral bleeds and ischaemic brain injury, often necessary in the resuscitation phase and occasionally needed during the maintenance phase of trauma victims, and required by all organ donors during the protracted surgery for organ procurement.
In Nygaard's series, the number of complications increased as the elapsed time between clinical brain death and organ procurement increased, indicating that once brain death certification has been performed, organ procurement should not be delayed. Ihle quotes that 8070 of his potential donors became haemodynamically compromised with loss of organs because of delays in organ procurements.
Given the scarcity of donor organs, it is important that once brain death has been diagnosed and consent for organ donation obtained, organs are maintained at their best possible level of function and organ procurement occurs as soon as possible. The better the function of the organs before retrieval, the better their function is likely to be following transplantation.
MANAGEMENT OF SPECIFIC PROBLEMS IN THE (POTENTIAL) ORGAN DONOR

Hypertension and catecholamine surges
For about one to two hours around the time of brainstem coning, there is an intense sympathetic "storm" associated with significant increases in circulating catecholamines which produces severe peripheral vasoconstriction and may result in acute left ventricular failure and pulmonary oedema.
In the Chacma baboon 6 , this occurred within five minutes of induction of brain death, and the level of circulating adrenaline rose elevenfold, noradrenaline threefold and dopamine twofold. It caused blood pressure to rise by almost 200070 and systemic vascular resistance (SVR) by more than 500070. Aortic blood flow dropped by 42 %.
Catecholamine levels returned to baseline within 15 minutes and fell below baseline by three hours. ECG changes may appear at the time of catecholamine surge. ST and T wave changes are commonly seen in patients with intracranial injury. These findings, often confused with myocardial ischaemia 7 , have been thought to be of no pathologic consequence. Novitzky8 however, believes that direct stimulation of the cardiac sympathetic plexus results in release of endogenous catecholamines and that this, rather than circulating catecholamines, results in increased calcium uptake by the myocardial cells inducing myocyte necrosis. Considerable myocardial structural damage is seen on light microscopy in 60% of baboons when hearts are excised 16 to 24 hours after brain death.
The histological features of myocardial damage following brain death are not dissimilar to those seen in early acute rejection. Novitzky believes that these may result in early failure of the donor heart following transplantation and that post-transplant endomyocardial biopsies in patients who have received hearts damaged during the donor's dying process may be misinterpreted as rejection.
Adrenalectomy did not prevent myocardial damage occurring, but total denervation of the heart (cardiac sympathectomy) results in a greatly modified haemodynamic response to brain death, with reduced tachycardia and abolition of ECG changes. These hearts showed no evidence of myocardial damage.
The stage of tachycardia and hypertension is usually short-lived and usually requires no treatment. It would appear from Novitzky's work that treatment of the hypertension does not prevent the development of myocardial damage. In humans, brainstem coning and the onset of brain death are commonly preceded by a period of hypertension and tachycardia. This period may be brief or last a few hours and is probably an adaptive response to preserve cerebral blood flow. Attempts to reduce blood pressure in these circumstances may be detrimental and are not usually recommended. Once coning occurs, this phase of hypertension is commonly followed by often profound hypotension. If lowering of blood pressure is considered necessary during the hypertensive phase, an agent with rapid onset and offset of action that is easily titrated, such as sodium nitroprusside, should be used. The use of long-acting hypotensive agents is contraindicated.
Following brain death, patients may still develop hypertension in response to noxious stimuli. This may be mediated by spinal sympathetic reflexes or by stimulation of the adrenal medulla by a reflex spinal Anaesthesia and Intensive Care. Vol. 23 . No. I. February. 1995 arc 9 • Similar responses to noxious stimuli can be seen in patients with a high spinal cord transection where activity within the cord may result in haemodynamic instability with changes in vascular tone and cardiac rate.
HYPOTENSION
This commonly occurs soon after brain death. The onset may be insidious or abrupt and contributory factors include: 1. absolute hypovolaemia: a) deliberate dehydration to decrease cerebral oedema, (mannitol, frusemide and fluid restriction), b) incomplete resuscitation following trauma and/or bleeding, c) inadequate replacement of essential and third space losses, d) diabetes insipidus with massive diuresis, e) osmotic diuresis secondary to hyperglycaemia (or mannitol): 2. effective hypovolaemia (maldistribution of volume): a) "neurogenic shock" with absent central vasomotor control, subsequent progressive loss of systemic vascular resistance, arterial vasodilatation and pooling of the intravascular volume in the venous capacitance vessels, b) the possible lack of anterior pituitary hormones resulting in decreased circulating catecholamines, c) rewarming of a hypothermic patient with resultant vasodilatation: 3. left ventricular dysfunction: secondary to trauma and myocardial contusion, or increased sympathetic stimulation as a result of coning of the brainstem. Renal ischaemia due to prolonged systemic hypotension is considered to be one of the major causes of kidney damage after brain death. Carrol lO showed that preventing hypotension improved the function of cadaveric kidneys.
Hypovolaemia is the commonest cause of hypotension and an inadequate cardiac output. Inotropic agents should not be used as a substitute for inadequate volume replacement and, if needed, high doses are usually not required once an adequate circulating blood volume has been restored. The effects of hypovolaemia (absolute or effective) must be countered and blood pressure returned to a level that ensures adequate tissue perfusion. This can usually be achieved with balanced salt solutions, but colloids may be required and blood transfused if the haematocrit drops to less than 35%. Trauma patients may often be severely haemodiluted. Severe anaemia worsens end-organ ischaemia and aggravates shock. This situation should be prevented and treated by the use of blood to correct anaemia. Provided that the haemoglobin concentration is > 10 g/dl, the choice of fluid will depend on the type and volume of the losses.
Great care must be taken with fluid replacement at this time, as often large volumes are required and there is already pre-existing hypernatraemia (deliberately induced for the treatment of cerebral oedema) which often coincides with the onset of hypothermia and diabetes insipidus. Unwarmed fluids will in these circumstances aggravate pre-existing hypothermia, or rapidly cause it. Excess salt solutions at a time of rapid water diuresis (from diabetes insipidus) will worsen the pre-existent hypernatraemia. Both these factors (temperature <3S0C and serum Na+ >160 mmolll) can preclude the certification of brain death, and their correction is usually slow and may involve many hours during which donor status may deteriorate. It is important to emphasize that although rapid and often large volume hydration is required, overhydration must be avoided as this may result in liver congestion 11 and deterioration in oxygenation secondary to pulmonary oedema l2
• Our first-line treatment of hypotention usually consists of boluses of colloids to achieve/restore CVP to lO-lS mm Hg in addition to often high-volume fluid replacement with either SOlo dextrose or sterile water depending on the degree of hypernatraemia, hyperglycaemia and the presence of diabetes insipidus (see below, sections on diabetes insipidus, hyperglycaemia and electrolytes). All replacement fluids are warmed and the patient is covered with a warming blanket.
Some centres promote the use of dextran 40, claiming the advantages are that dextran 40 maintains plasma volume, achieves moderate haemodilution, improves microcirculation and tissue oxygenation and decreases the risk of thromboembolic complications I3 ,14. However, the majority of organ donors do not receive this, as no benefit has been clearly demonstrated.
Patients whose central venous pressure (CVP) is greater than IS mmHg and who have valvular heart disease, cardiomyopathy, pulmonary oedema, left ventricular dysfunction, persistent hypotension or a high PEEP requirement have often had a pulmonary artery catheter inserted, and measurements taken from this will help guide further therapy.
Haemodynamic heterogeneity is a characteristic of brain dead organ donors and that instability is present to varying degrees l '. If hypotension persists despite fluid loading, or is severe, vasodilatation will need to be reversed.
The use of dopamine and other inotropic drugs is not recommended by some centres 8 • 16 on the basis of two theoretical concerns: a) catecholamine-induced donor cardiomyopathy (because of down-regulation of receptor sites or post-receptor influences) and b) catecholamine depletion of the myocardium through endogenous release of noradrenaline resulting in an attenuated response to subsequent exposure to catecholamines. Despite these concerns, inotropic drugs are frequently required to maintain an adequate blood pressure. Many centres use dopamine as the first-line agent. At low dose, it is a renal vasodilator which may be of benefit to the kidneys, but may aggravate the already large diuresis occurring secondary to diabetes insipidus. At low doses, it also dilates mesenteric blood vessels and this may be beneficial as it improves pancreatic and hepatic blood flow. Low-dose dopamine alone however, is rarely sufficient to correct hypotension. At high doses (> 10 /Lg/kg/min), the above advantages are lost and dopamine becomes a pure alpha agonist.
Beta adrenergic agonists such as dobutamine and isoprenaline are usually contraindicated (and if used, poorly tolerated) because they vasodilate the peripheral vascular bed, and peripheral vasodilatation is already a problem. They do have a role if hypotension is secondary to cardiac injury and myocardial dysfunction.
Alpha agonists are commonly required. In high doses, they may cause peripheral vasoconstriction, accentuating acidosis and tissue hypoperfusion. Both adrenaline and noradrenaline lead to vasoconstriction and therefore, to protect the kidneys and mesenteric blood flow, are often used in conjunction with low-dose dopamine, although the "protective" effect of dopamine in these circumstances is not confirmed l7 . 18. Noradrenaline will also decrease hepatic blood flow and thus possibly compromise hepatic function. Both adrenaline and noradrenaline will increase hyperglycaemia. If inotropes are req uired, our practice is to commence with low-dose dopamine, increasing the infusion rate as required. If blood pressure aims are not achieved with infusions of 10 /Lg/kg/min, the dopamine is reduced to a "renal dose" of 3-4 /Lg/kg/min and adrenaline is commenced. If the potential organ donor remains hypotensive despite moderate doses of adrenaline, a noradrenaline infusion is added. Endocrine dysfunction may also contribute to circulatory instability. Howlett l9 in his series of 30 consecutive brainstem dead donors, found that those with severe hypotension did not have significantly lower serum cortisol levels. Only 1 of 20 patients not receiving corticosteroids had un detectable levels of serum cortisol consistent with adrenocorticotrophic hormone (ACTH) deficiency. One donor had a level below normal resting range, 13 within the normal resting range and five were in the range of 710 to 880 nmollI. These values suggest that there was not complete ACTH deficiency, but the values were much lower than expected for the degree of "stress" and certainly cortisol-deficiency may have contributed to the hypotension. In the haemodynamically unstable patient, already fluid-loaded and receiving high doses of inotropes, it may well be worthwhile to try steroid replacement. In this circumstance, our practice is to give an initial dose of 250 mg of hydrocortisone intravenously followed by a hydrocortisone infusion of 5 mg per hour. Kinoshita 20 found that the addition of arginine vasopressin (0.3 mU/kg/min) to adrenaline resulted in the circulation being maintained with smaller doses of adrenaline, renal function remained normal and did not deteriorate, and donors could be maintained for up to 14 days (compared with the control group who were treated with adrenaline alone and experienced cardiac arrest within 48 hours). Kinoshita proposes that there is a special interaction between anti-diuretic hormone and adrenaline that increases vascular tone and cardiac output and that this effect leads to longterm haemodynamic stability after brain death. Although creatinine clearance was kept within the normal range, serum sodium concentration gradually decreased. There was no derangement in liver function with regard to enzymes nor was there any rise in serum amylase as a result of mesenteric ischaemia.
Yoshioka 21 maintained haemodynamic stability in brain dead patients for 23 ± 19 days with continuous infusions of vasopressin (1-2 Units/hour) and low-dose adrenaline (0.5 mg/hr) to keep the systolic BP above 90 mmHg. This could not be achieved with adrenaline alone, suggesting that anti-diuretic hormone (ADH) plays an important role in haemodynamic stability when vasomotor impulses are absent.
Cowley22 reported that in decapitated animals on a small continuous infusion of noradrenaline and given ADH at physiological doses (non pressor doses), pressor sensitivity was increased nearly 8000 fold.
In children, once the dose of noradrenaline exceeds 0.5 p.g/kg/min, vasopressin is used routinely to help maintain blood pressure. In adults, we do not recommend the routine use of vasopressin for the control of hypotension, but if hypotension persists despite fluid loading, inotropic drugs and steroids, it is worth considering. In practice, because of the presence of diabetes insipidus in most potential organ donors, they are already receiving vasopressin, but this is often in the form of desmopressin (1-desamino-8-Darginine vasopressin, DDAVP) which has little pressor activity and in these circumstances, should be changed to arginine vasopressin. 
DIABETES INSIPIDUS
Lack of central secretion of ADH will result in an inappropriate, frequently massive urine output that bears no relationship to the intravascular fluid volume. Haemodynamic instability may then occur secondary to hypovolaemia or electrolyte disturbances.
A sudden inappropriate polyuria following deterioration of neurological status is strongly suggestive of diabetes insipidus (01). A low urinary sodium ( < 10 mmolll) in the presence of hypernatraemia is usually sufficient to confirm the diagnosis provided that one first excludes a diuresis secondary to fluid loading, mannitol, hyperglycaemia, diuretics and inotropes in which the urinary [Na +] is usually >40 mmollI. (N.B. the urinary [Na+] in the latter may become < 10 mmolll if hypovolaemia ensues).
The formal diagnosis of 01 consists of: hypernatraemia associated with a plasma osmolality > 300 mosmolll and hypotonic polyuria (> 4 mllkg/hour) with a urine sa < l.005 or a urine osmolality < 300 mosmollI.
The incidence of 01, although quite common, is not universal and has been quoted to vary from 8.5 to 87010 2 • Novitsky23 however, found that in all baboons studied, there was a significant fall in ADH levels, ADH disappearing from the plasma within six hours of brain death. In our experience, 01 occurs in the vast majority of potential organ donors, usually commencing shortly after, but occasionally before the onset of brain death.
If not properly treated, DJ will result in metabolic derangements including serum hyperosmolarity, hypernatraemia, hypomagnesaemia, hypokalaemia, hypophosphataemia, and hypocalcaemia. The management of 01 requires frequent monitoring, not only of serum electrolytes and glucose, but also of urine output and urinary electrolytes.
Common practice is to replace the previous hour's urine output with a hyponatraemic fluid. This, when done on its own, invariably results in a) ever-increasing urine outputs and b) hyperglycaemia if rapid infusion of large volumes of glucose-containing fluid are administered to a patient who is often already receiving inotropes and likely to be glucose intolerant. The hyperglycaemia in turn will lead to an osmotic diuresis. In addition, urine outputs of more than 200 mllhour will not only result in major biochemical and electrolyte disturbances, but also complicate fluid management by requiring large volumes of fluid replacement which in turn will worsen hypothermia unless all infused fluids are adequately warmed.
Our recommendations for the management of 01 are: 1) Replace previous hour's urine output in combination with enough fluid to correct the water deficit and hypernatraemia and prevent hypovolaemia from developing. This will commonly require more than 200 mllhour of sodium-free fluid and as much as 1000 mllhour may be needed. In the latter situation this should be given as warmed sterile intravenous water as similar volumes of 5070 dextrose will cause marked hyperglycaemia. Large volume infusions of sterile water can safely be given via a central venous catheter with minimal risk of haemolysis 24 • 2) If urine output is greater than 200 mllhour, ADH should be administered. Arginine vasopressin (AVP) is not innocuous. Side-effects include splanchnic vasoconstriction which may be detrimental to hepatic and pancreatic blood flow, and increased smooth muscle contractility which may adversely affect coronary and pulmonary blood flow. It is available in an aqueous form with a short half-life that can be given subcutaneously, intramuscularly, intravenously and intranasally, and as vasopressin tannate in oil, which has a much longer duration of action but can only be administered intramuscularly. Administration by the intramuscular, subcutaneous and intranasal routes is contraindicated as it results in variable absorption and cumulative effects. The intravenous route is recommended as it is easily titrated. It may be given as a continuous low-dose infusion, or as intermittent bolus doses. Large doses however, should not be used as renal shut-down may occur. Care must be taken when vasopressin and hypotonic fluids are administered simultaneously so as not to cause hyponatraemia. An alternative method of treating DI, which is virtually self-regulating, has been proposed by Ralston and Butt 25 • They insert two units of aqueous vasopressin in a litre of the appropriate intravenous solution and infuse the resultant mixture to replace 80 to 110070 of the previous hour's urine output. This becomes self-regulating as the greater the urine output, the more vasopressin administered, and the less the urine output, the less vasopressin administered. With this protocol, polyuria, hypernatraemia and decreased urine osmolalities were safely corrected in all patients within 8 to 28 hours. DDAVP has enhanced anti-diuretic potency, greatly diminished pressor activity and a prolonged halflife and duration of action compared with arginine vasopressin. The ratio of its anti-diuretic to pressor potency is 2000:1 compared with AVP, and its duration of action is 6 to 20 hours compared with 2 to 6 hours. For these reasons, intravenous DDAVP may be the preferred form of anti-diuretic hormone for treating DI where refractory hypotension is not a problem. 3) Once a urine output of less than 200 mllhour is achieved, metabolic homeostasis can usually be maintained with the use of either 5070 dextrose or 4070 dextrose in 0.2070 saline infusions. The serum glucose level will need careful monitoring as elevated levels are common. If blood glucose rises to levels greater than 15 mmolll, an insulin infusion is commenced. If blood glucose remains uncontrolled despite 4 to 5 Units of insulin per hour, we would then again commence an infusion of sterile water and decrease the rate of dextrose infusion.
HYPERGLYCAEMIA Masson 26 in his study of 25 consecutive organ donors concluded that pancreatic endocrine function was not affected by brain death. Hyperglycaemia was associated with elevated insulin and C-peptide levels. Histologic and immunohistochemical examinations of the pancreas were available in 17 cases and were considered normal. They found no evidence of pancreatic insufficiency directly linked to brain death. Hyperglycaemia is multi-factorial and probably relates to a combination of insulin resistance as a consequence of stress and inotropic infusions (catecholamine effect) and rapid administration of large volumes of glucose containing fluids to replace the fluid losses of DI.
Hyperglycaemia increases osmolality and leads to an osmotic diuresis with further loss of water and electrolytes. It can often be avoided by keeping dextrose infusions to less than 200 mllhour. Glucose levels persistently in excess of 15 mmolll should be treated with insulin. The intramuscular and subcutaneous routes of insulin administration may produce unreliable absorption, and therefore intravenous infusions are preferred.
ELECTROLYTES
Electrolytes require regular and frequent monitoring. Hypernatraemia with associated hypomagnesaemia, hypokalaemia, hypocalcaemia, and hypophosphataemia are the commonest abnormalities encountered and are secondary to major urinary losses in uncontrolled DI. These derangements should be prevented, as they will, if severe enough, interfere with organ function and viability.
Hyponatraemia is uncommon. It is usually artefactual and secondary to hyperglycaemia, but may be non-artefactual, e.g. the result of the simultaneous administration of hypotonic fluids and ADH. It may also be seen in hypoadrenal and hypothyroid states.
HYPOTHERMIA
Core temperature must be monitored by oesophageal, rectal or bladder probe because hypothermia is very common and has severe consequences. Established brain death results in depressed metabolism, failure to compensate for heat losses because of lack of shivering, the inability to vasoconstrict, and therefore a poikilothermic patient. Hypothermia is greatly aggravated by the use of large volumes of intravenous fluids and blood products which are commonly infused at room or refrigerator temperatures to replace the large fluid losses seen with DIor to correct anaemia. It may develop rapidly, and once present, is usually difficult and slow to correct. This may preclude certification of brain death as this requires the core temperature to be greater than 35°C.
Coagulopathy occurs if temperature is less than 32°C. Furthermore, hypothermia decreases the renal tubular concentration gradient and leads to a cold diuresis. It also shifts the oxyhaemoglobin dissociation curve to the left leading to decreased oxygen delivery. The main adverse effect of hypothermia however is on the heart where it results in myocardial depression, hypotension, progressive bradycardia, cardiovascular instability and finally cardiac arrest. Temperatures of less than 28°C are associated with ventricular irritability and arrhythmias often refractory to treatment. Bretylium is the drug of choice in these circumstances.
Treatment of hypothermia is essential. Prevention of hypothermia however is much preferred as, once it occurs, the time delays involved in the correction of hypothermia (in order to certify brain death) may result in deterioration of the potential organ donor. The patient must be warmed with blankets, aluminium foil (shiny side in towards the patient) to reflect radiant heat and to prevent convective heat losses. It is important to place foil (and heat) over the head as significant heat loss occurs from the scalp. Passive warming is usually not sufficient to correct hypothermia. Active measures include the use of warming blankets, warming of blood and intravenous fluids, and the use of heated humidifiers in ventilator circuits. Sometimes it may even be necesssary to institute warm gastric or bladder lavage to achieve a temperature greater than 35°C.
Hyperpyrexia may occur during the initial phase of brainstem injury, but is usually short-lived and rarely requires treatment once brain death has occurred.
Poikilothermia means that it is also possible, although unusual, for a patient to be overheated. Simply taking off some of the coverings will allow the patient's temperature to fall. 
ARRHYTHMIAS
Delays in organ procurement following brain death must be avoided as haemodynamic instability (hypotension and arrhythmia) is a continuing threat. Despite all efforts to maintain the donor's circulation, terminal arrhythmias refractory to therapy will occur, usually within 48-72 hours 27 of declaring brain death.
Like many of the other problems occurring following brain death, mUltiple factors may be involved.
These include: 1. electrolyte disturbances, in particular: hypocalcaemia, hypomagnesaemia, hypokalaemia and hypophosphataemia occurring secondary to DI, 2. hypovolaemia, hypotension and secondary myocardial ischaemia, 3. acidosis secondary to hypoperfusion and anaerobic metabolism, 4. hypoxia secondary to lung disease, 5. hypothermia, 6. pro-arrhythmic properties of inotropes, 7. myocardial contusion.
Progressive slowing of atrial and junctional pacemakers without any ventricular escape rhythm or various degrees of A-V block are common. Bradyarrhythmias causing hypotension are resistant or refractory to parasympatholytic effects of atropine 28 and require chronotropes or, uncommonly cardiac pacing. For tachyarrhythmias, bretylium sometimes works as an anti-arrhythmic when other agents fail.
Logigian 7 described three patterns of terminal rhythms: 1) patients who developed A-V block progressed to complete heart block without a ventricular response (atrial activity alone), 2) patients who remained in sinus rhythm developed ventricular tachycardia followed by ventricular fibrillation, and 3) those patients with sinus bradycardia progressed directly to asystole.
In order to minimize the risk of arrhythmias, electrolyte and biochemical derangements should be corrected by measuring and subsequently replacing those substances found to be deficient. Hypotension is treated by fluid loading and inotropes as required. In order to avoid vasoconstriction, the doses of inotropes should be kept to a minimum. Optimizing the circulation and improving oxygen delivery will usually correct anaerobic metabolism secondary to hypoperfusion. Ventilation can also be adjusted to correct pH. There is some evidence that inducing alkalosis, particularly in the presence of hypothermia, will decrease the incidence of ventricular fibrillation. Active steps should be taken to keep the patient warm. RESPIRATION Some measures used to protect the brain before brain death occurs may be detrimental to other organ function. Hyperventilation decreases P aC02 and is used to lower intracranial pressure, but it causes peripheral vasoconstriction and may compromise organ function. Hyperventilation should be ceased once brain death has occurred.
Hypoxaemia may be cardiac, neurogenic, or pulmonary in origin and is also detrimental to good organ function. Cardiogenic pulmonary oedema is uncommon but can be confirmed by the haemodynamic measurements taken from a pulmonary artery catheter and will improve with a diuresis. More commonly, pulmonary oedema is due to adult respiratory distress syndrome (ARDS) or is neurogenic in origin, developing rapidly and secondary to the increased sympathetic nervous system activity that occurs during the onset of brain death. Oxygenation in non-cardiogenic pulmonary oedema is unlikely to improve with "drying out" which is likely to compromise the perfusion of other organs. All forms of pulmonary oedema will respond to positive end expiratory pressure (PEEP).
COAGULOPATHY
The release of tissue fibrinolytic agents from ischaemic/necrotic brain into the circulation probably initiates disseminated intravascular coagulation which will aggravate any bleeding problems. Clotting factors need to be replaced as required, platelets infused to keep the platelet count above 50 x 10 9 /1, and red blood cells to keep the haemoglobin greater than 10 g/dl.
The use of E-aminocaproic acid is not recommended as microvascular thrombosis may be induced in the donor organs.
ENDOCRINE DISTURBANCE
The problem of hormone deficiencies following brain death and whether or not replacement is required is far from clear. Findings are inconsistent. Brain death interrupts the hypothalamic/pituitary axis and consequently may result in hypothyroidism and adrenal insufficiency.
Novitzky29-31 has shown in both human and animal studies that following brain death there is a rapid depletion of ADH, circulating triiodothyronine (T3), thyroxine (T4), cortisol and insulin. Thyroid hormone levels fell to 50070 of baseline at one hour and became undetectable at 14 hours following brain death. Thyroid stimulating hormone (TSH) obviously did not rise.
They showed that brain death resulted in increased anaerobic metabolism with a progressive lactic acidosis requiring 1) increasing inotropic support without concomitant improvement in haemodynamics, and 2) increasing doses of bicarbonate to maintain a physiologic pH.
They postulated that the cardiac instability and deterioration in renal function that ensued after brain death was secondary to the acidosis, and claimed that hormonal therapy with intravenous T3 (2-4 fLg/15 min to 2 hr), cortisol (100 mg/l to 2 hr) and insulin (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) Units/l to 2 hr) resulted in a return to aerobic metabolism, replenishment of energy stores (ATP), return to organ functional stability, return to normothermia, improved myocardial function and improvement in or complete resolution of ECG abnormalities. The requirement for inotropes and bicarbonate decreased significantly following hormonal therapy. Novitzkyand associates 32 recommend routine use of T3 in all donors and recipients of cardiac allografts.
Papworth HospitaP3 has developed a "Hormone Package" consisting of tri-iodothyronine, anti-diuretic hormone and insulin which is given as a continuous infusion, and have demonstrated marked improvements in cardiac function compared to that in untreated patients.
Wahlers 34 found that postoperatively, recipients of hearts from hormone-depleted donors required significantly higher doses of dopamine and for longer than the recipients of hearts from donors not hormonedepleted.
Wicomb 35 using a pig model of a donated kidney, found that the addition of T3, cortisol and insulin significantly improved renal function.
Opposite findings were reported by Powner 36 who compared 14 significantly brain injured patients (GCS < 7) who did not develop brain death with 16 patients who became brain dead. He found no significant changes in hormone levels as a result of brain death. The abnormalities in thyroid function were considered secondary to the sick euthyroid syndrome rather than TSH deficiency. Blood levels of TSH were normal in all 16 brain dead patients. As the half-life of TSH is about 35 minutes, this suggested that production of TSH had not ceased. Hypothyroidism did not appear to occur. Schrader 37 also found blood levels of all anterior pituitary hormones to be normal up to twenty hours after angiographically documented brain death in six patients. These findings have also been confirmed by Howlett l9 •
We rarely see the progressive lactic acidosis reported by Novitzk y29-31 following brain death and it is not our practice to routinely replace T3 or cortisol. In the difficult patient with haemodynamic instability, or in the organ donor requiring prolonged support prior to organ retrieval, it may be worth considering.
CONCLUSION
The appropriate management of the brain dead potential organ donor is time-consuming, complex and challenging. It involves recognition and subsequent confirmation of a potential donor, certification of brain death, a knowledge of the legal formalities, obtaining consent from the grieving relatives, organization of organ procurement, whilst throughout supporting the potential donor. It involves stepping in and reversing the natural processes that result in somatic death. It requires major interventions to reverse hypotension, control DI, prevent hyperglycaemia, maintain normal electrolytes, prevent and correct hypothermia, prevent arrhythmias, optimize ventilator management, correct coagulopathy and decide whether or not to replace the hormones of the failing endocrine system. The reward is the successful procurement of multiple well-functioning organs that can then be transplanted with good function and outcome.
